Perspective of gene therapy with replication competent viruses.
作者信息
Maemondo Makoto
机构信息
Division of Pulmonary Medicine, Allergy and Rheumatology, Iwate Medical University, Iwate, Japan.
出版信息
Transl Lung Cancer Res. 2020 Dec;9(6):2511-2513. doi: 10.21037/tlcr-20-547.
Abstract
摘要
相似文献
1
Perspective of gene therapy with replication competent viruses.
Transl Lung Cancer Res. 2020 Dec;9(6):2511-2513. doi: 10.21037/tlcr-20-547.
2
Enhancing radiotherapy with genetically engineered viruses.
J Clin Oncol. 2007 Sep 10;25(26):4090-5. doi: 10.1200/JCO.2007.12.2739.
3
Construction of a replication-competent hepatitis B virus vector carrying secreted luciferase transgene and establishment of new hepatitis B virus replication and expression cell lines.
World J Gastroenterol. 2019 Oct 21;25(39):5961-5972. doi: 10.3748/wjg.v25.i39.5961.
4
Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.
Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908-E7916. doi: 10.1073/pnas.1617789113. Epub 2016 Nov 21.
5
Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
J Gene Med. 1999 May-Jun;1(3):176-85. doi: 10.1002/(SICI)1521-2254(199905/06)1:3<176::AID-JGM35>3.0.CO;2-T.
6
Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.
Cancer Gene Ther. 2015 Sep;22(9):445-53. doi: 10.1038/cgt.2015.33. Epub 2015 Aug 7.
7
Cytolytic viruses as potential anti-cancer agents.
J Gen Virol. 2002 Mar;83(Pt 3):491-502. doi: 10.1099/0022-1317-83-3-491.
8
Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy.
Cell Cycle. 2006 Jul;5(14):1531-6. doi: 10.4161/cc.5.14.3095. Epub 2006 Jul 17.
9
Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.
Crit Rev Oncol Hematol. 2001 Jun;38(3):177-92. doi: 10.1016/s1040-8428(01)00103-2.
10
Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
J Gene Med. 2008 Apr;10(4):340-54. doi: 10.1002/jgm.1157.
引用本文的文献
1
Viruses as tools in gene therapy, vaccine development, and cancer treatment.
Arch Virol. 2022 Jun;167(6):1387-1404. doi: 10.1007/s00705-022-05432-8. Epub 2022 Apr 24.
本文引用的文献
1
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study.
J Thorac Oncol. 2020 Jan;15(1):110-119. doi: 10.1016/j.jtho.2019.09.083. Epub 2019 Oct 9.
2
Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
J Clin Invest. 2017 Aug 1;127(8):2957-2967. doi: 10.1172/JCI93472. Epub 2017 Jun 26.
3
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.
Pediatr Blood Cancer. 2015 May;62(5):743-50. doi: 10.1002/pbc.25269. Epub 2014 Oct 12.
4
Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer.
Cancer Gene Ther. 2011 Jun;18(6):444-9. doi: 10.1038/cgt.2011.15. Epub 2011 Apr 1.
5
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
Clin Cancer Res. 2011 Feb 15;17(4):888-95. doi: 10.1158/1078-0432.CCR-10-1706. Epub 2011 Feb 8.
6
Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.
J Zhejiang Univ Sci B. 2009 May;10(5):331-40. doi: 10.1631/jzus.B0820248.
7
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
PLoS One. 2008 Jun 18;3(6):e2409. doi: 10.1371/journal.pone.0002409.
8
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33. doi: 10.1093/jnci/djm198. Epub 2007 Oct 30.
9
Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
Cancer Res. 2004 Jul 1;64(13):4611-20. doi: 10.1158/0008-5472.CAN-03-2549.
10
Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
Cancer Gene Ther. 2002 Dec;9(12):979-86. doi: 10.1038/sj.cgt.7700539.
Zotero 插件